Le Lézard
Classified in: Health, Business
Subjects: JVN, POL

ESMO and ASCO Call on Governments to Improve Cancer Services and Reduce Cancer Deaths


LUGANO, Switzerland, July 5, 2018 /PRNewswire/ --

The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO), the world's two leading organisations for oncology professionals, today issued a joint statement calling upon governments to renew political commitment to improve cancer services and reduce cancer deaths.

The statement was issued on the occasion of the United Nations Civil Society Hearing on non-communicable diseases (NCDs)[1] in New York.

"As cancer doctors we work hard every day to ensure that patients receive the best possible care," said Alexandru Eniu, Chair of the ESMO Global Policy Committee. "We are progressively increasing our knowledge about cancer and how to treat it. We can even cure some cancers if we intervene early enough."

"However, in many countries access to even the most inexpensive essential cancer medicines and priority medical devices is lacking," warned Eniu. "We urgently need governments to work with us and ensure that we have enough oncology professionals, and the necessary resources, to apply our knowledge and save lives."

ESMO President, Josep Tabernero added, "Recent UN and WHO reports [2],[3],[4],[5] note that unless countries significantly scale-up their actions and investments, they will not meet agreed targets to reduce deaths from non-communicable diseases. We are concerned that governments may find it easier to achieve their targets by reducing deaths from only some NCDs, leaving cancer patients behind. We believe there are cost-effective ways to improve cancer care and stand ready to assist countries in doing this by providing our expertise in cancer management to support implementation of the 2017 World Health Assembly Cancer Resolution."

"We urge Member States to consider our joint call and amendments to strengthen the Political Declaration to be approved during the UN High-Level Meeting on 27 September and thus change the future outlook for cancer patients worldwide," Tabernero concluded.

About the European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology. With 18,000 members representing oncology professionals from over 150 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.

References: 

[1] Noncommunicable diseases (NCDs), also known as chronic diseases, include cancers, cardiovascular diseases, chronic respiratory diseases and diabetes. For more information see WHO key facts about Non-Communicable Diseases

[2]United Nations Report by the Secretary General, Document A_72_662, 21 December 2017

[3]World Health Assembly Report by the WHO Director General, Document WHA 71.2, 26 May 2018

[4]WHO Independent High-Level Commission on NCDs Report, Time to Deliver, 1 June 2018

[5]WHO Report Saving Lives, Spending Less, 21 May 2018


Contact:
ESMO Press Office
Vanessa Pavinato
+41-91-973-19-07
[email protected]

SOURCE European Society for Medical Oncology (ESMO)


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: